Bioavailability of Xanthones From Mangosteen
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition |
|---|
|
Healthy Volunteers |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Bioavailability and Anti-inflammatory Activities of Mangostins: a Pilot Study |
- Xanthones in urine [ Time Frame: 0-24 hours ] [ Designated as safety issue: No ]Urine was collected prior to ingesting mangosteen juice with breakfast and then from consumpotion of juice until 24h.
- Xanthones in sera [ Time Frame: 0-24 hours ] [ Designated as safety issue: No ]Blood was collected prior to breakfast, and 1, 2, 3, 4, 6, 8 and 24 hours
Biospecimen Retention: Samples Without DNA
| Enrollment: | 10 |
| Study Start Date: | November 2010 |
| Study Completion Date: | February 2011 |
| Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Females ingesting mangosteen juice |
| Males ingesting mangosteen juice |
Detailed Description:
Garcinia mangostana L. (mangosteen) is a tropical tree native to Southeast Asia. The pericarp of mangosteen fruit is used in traditional medicine to treat inflammation, infections, wounds, and diarrhea. The proposed health-promoting effects have been attributed to a family of polyphenols referred to as xanthones. Since its introduction into the United States, juices and products containing mangosteen fruit have become a top-selling botanical dietary supplement. This commercial success largely has been the result of aggressive marketing of health claims based on in vitro observations and anecdotal reports.
The purpose of this study was to determine the bioavailability of xanthones from mangosteen juice in adult human subjects. After an overnight fast of at least 10h, male and female subjects were admitted to the Ohio State University Clinical Research Center. Volunteers ingested 2 ounces of 100% mangosteen juice as part of a western-style breakfast. Pericarp particles accounted for 1% of the mass and 99% of total xanthone content in the juice. This dose provided 130 ± 2 mg total xanthones. Blood was collected prior to breakfast and 1,2,3,4,6,8 and 24h. Subjects were fed a mangosteen-free lunch and released from the unit after the 8h collection, refraining from mangosteen containing products until final collection of blood at 24h. Urine was collected for the 24 test period.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- 5 female
- 5 male
- body mass index </= 30
- normal renal function
- non-smoking
Exclusion Criteria:
- smokers
- acute or chronic diseases
- history of gastrointestinal diseases
- >/= 10% weight loss
- dietary or herbal supplement within 6 months of study
- pregnancy
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01425047
| United States, Ohio | |
| The Ohio State University, Clinical Research Center | |
| Columbus, Ohio, United States, 43210 | |
| Principal Investigator: | Mark Failla, PhD | Ohio State University |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Mark Failla, Professor, Human Nutrition, Associate Dean for Research, The Ohio State University |
| ClinicalTrials.gov Identifier: | NCT01425047 History of Changes |
| Other Study ID Numbers: | 2010H0219 |
| Study First Received: | August 26, 2011 |
| Last Updated: | August 31, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Ohio State University:
|
mangosteen xanthones dietary supplement |
botanical supplement bioavailability Determine bioavailability of mangosteen xanthones in adults |
ClinicalTrials.gov processed this record on September 27, 2016